• support@madhedgefundtrader.com
  • Member Login
Mad Hedge Fund Trader
  • Home
  • About
  • Store
  • Luncheons
  • Testimonials
  • Contact Us
  • Click to open the search input field Click to open the search input field Search
  • Menu Menu
Mad Hedge Fund Trader

Trade Alert - (BRKB) May 19, 2021 - BUY

Trade Alert

When John identifies a strategic exit point, he will send you an alert with specific trade information as to what security to sell, when to sell it, and at what price. Most often, it will be to TAKE PROFITS, but, on rare occasions, it will be to exercise a STOP LOSS at a predetermined price to adhere to strict risk management discipline. Read more

https://www.madhedgefundtrader.com/wp-content/uploads/2016/02/Alert-e1457452190575.jpg 135 150 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2021-05-19 13:04:092021-05-19 14:10:10Trade Alert - (BRKB) May 19, 2021 - BUY
Mad Hedge Fund Trader

Trade Alert - (GS) May 19, 2021 - BUY

Trade Alert

When John identifies a strategic exit point, he will send you an alert with specific trade information as to what security to sell, when to sell it, and at what price. Most often, it will be to TAKE PROFITS, but, on rare occasions, it will be to exercise a STOP LOSS at a predetermined price to adhere to strict risk management discipline. Read more

https://www.madhedgefundtrader.com/wp-content/uploads/2016/02/Alert-e1457452190575.jpg 135 150 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2021-05-19 12:41:212021-05-19 12:41:21Trade Alert - (GS) May 19, 2021 - BUY
Douglas Davenport

May 19, 2021

Diary, Newsletter, Summary

Global Market Comments
May 19, 2021
Fiat Lux

Featured Trade:
(NINE SURPRISES THAT COULD KILL OFF THIS BULL MARKET),

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 Douglas Davenport https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Douglas Davenport2021-05-19 08:04:462021-05-19 07:56:55May 19, 2021
Douglas Davenport

Nine Surprises that Could Kill Off This Bull Market

Diary, Newsletter

I have lately been besieged with emails from readers asking if they should sell everything, put all their money into cash, and if the great bull market is well and truly over.

My answer is the same to all. If a full-throated and affirmative “NOT YET”. Things may look scary now, but they could get a lot worse, and eventually, that will take place, maybe by 2030.

But if 50 years of trading has taught me anything, it is always be prepared for the “black swan”. I have a laundry list of issues that could kill the bull once and for all. And while some of them are flashing alarm signals, many aren’t. I’ll go through them one by one.

The Pandemic Gets a Fourth Wave – Shutting down much of the economy and preventing kids from going back to school. As the stimulus tap (call it what it really is, disaster rescue) runs dry, tens of millions will lose jobs….again. Stocks could make a secondary low similar to the one we saw in 2020.

A New Pandemic Emerges – We may learn that the price of a globalized economy is more frequent pandemics. A greater mixing of global peoples is creating brand new pathogens from scratch at an unprecedented rate. We’ve had four new fatal bug attacks in the last 20 years. Before that, a serious one came along only every 20 years. It took six months for the 1918 Spanish Flu to spread around the world. Covid-19 took about a week. All of a sudden it went from southern China to rural northern Italy to remote eastern Colorado.

Cyber Terrorism – Has been brought to the fore once again by the Colonial Pipeline hack, which cut off gasoline supplies for much of the US East Coast. In the end, a $5 payment got the gas pumps flowing again. Imagine that you sat down to turn on your computer one day and nothing happened. The entire Internet was down, all financial transactions ceased, the power went out, and all food distribution ceased. America’s Internet infrastructure is far more vulnerable than most people realize. That's why I have been recommending cybersecurity stocks like Palo Alto Networks (PANW) and Snowflake (SNOW) for the past decade. Certainly, my own local utility, PG&E (PGE) doesn’t maintain security to a military standard. It should. That’s why I’m off the grid.

Debt Levels in China – It’s easy to forget that perhaps 40% of China’s government-owned financial institutions are de facto bankrupt. They have been accumulating bad loans for decades and hiding them on their balance sheets and essential negative net worth’s. If one suddenly goes under, it could easily lead to a cascading series of bankruptcies much like we saw in the US during the 2008 financial crisis that spills over to the US and Europe. Back then, we lost Lehman Brothers and Bear Stearns, and could have lost everyone if the government hadn’t stepped in.

Debt levels in the US – If Biden gets everything he wants with economic stimulus bills, the US national debt will soar from $28.2 to $40 trillion by 2025. With the ten-year US Treasury bond yielding a paltry 1.64%, the markets don’t see this as a problem….for now. When it does, bond yields could rocket to 5%-10% and stocks will crash. Maintain a core short position in the (TLT) as insurance.

2024 Election – is going to be loaded with fireworks for sure since they’re still counting votes from the last one. The rancor may get so extreme on both sides that it literally scares people out of the market. If Trump gets reelected, you can count on the stock market dropping by half in months. We barely survived the last round, when the Dow Average crashed 12,000 points in six weeks and 586,000 died.

Middle East War – War with Iran, always on the table, will be an enormous drag on the US economy. Investment shifts from machinery to weapons, which have no impact on productivity. Government borrowing soars more.

Biden Dies – Not an impossibility for a 78-year-old man in the highest-pressure job in the world. The current lifespan for American white males is, you guessed it, 78. Vice president Kamala Harris will take over but lacks the market soothing experience, the credibility, and the electability of Biden. Expect a headline shock.

Climate Change Accelerates – That is already happening but is hurting countries closer to the equator than ourselves, like India and Egypt. I just installed a new electric Mitsubishi mini-split heat pump to protect against the record temperatures of the coming summer. The US military certainly considers this an existential threat. Increased category five hurricanes, heat-caused crop failures, uncontrollable wildfires, and more frequent out-of-the-blue flooding are already having catastrophic localized effects. Imagine all that getting much worse. And there are severe impacts which we haven’t even thought about yet. The first effect we have already seen? Higher insurance premiums for everyone. Good luck getting new fire insurance in California or flood insurance in Florida. Mine just went up 40%.

https://www.madhedgefundtrader.com/wp-content/uploads/2014/03/John-Thoms-Black-Swans-e1413901799656.jpg 337 400 Douglas Davenport https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Douglas Davenport2021-05-19 08:02:302021-05-19 07:57:25Nine Surprises that Could Kill Off This Bull Market
Mad Hedge Fund Trader

Trade Alert - (SPY) May 18, 2021 - SELL-BUY

Trade Alert

When John identifies a strategic exit point, he will send you an alert with specific trade information as to what security to sell, when to sell it, and at what price. Most often, it will be to TAKE PROFITS, but, on rare occasions, it will be to exercise a STOP LOSS at a predetermined price to adhere to strict risk management discipline. Read more

https://www.madhedgefundtrader.com/wp-content/uploads/2016/02/Alert-e1457452190575.jpg 135 150 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2021-05-18 15:59:242021-05-18 15:59:24Trade Alert - (SPY) May 18, 2021 - SELL-BUY
Mad Hedge Fund Trader

Trade Alert - (QQQ) May 18, 2021 - BUY

Tech Alert

When John identifies a strategic exit point, he will send you an alert with specific trade information as to what security to sell, when to sell it, and at what price. Most often, it will be to TAKE PROFITS, but, on rare occasions, it will be to exercise a STOP LOSS at a predetermined price to adhere to strict risk management discipline. Read more

https://www.madhedgefundtrader.com/wp-content/uploads/2016/02/Alert-e1457452190575.jpg 135 150 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2021-05-18 15:52:152021-05-18 15:52:15Trade Alert - (QQQ) May 18, 2021 - BUY
Mad Hedge Fund Trader

May 18, 2021

Biotech Letter

Mad Hedge Biotech & Healthcare Letter
May 18, 2021
Fiat Lux

FEATURED TRADE:

(AN UP-AND-COMER BIOPHARMA STOCK)
(ABBV), (ABT), (JNJ), (PFE)

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2021-05-18 15:02:222021-05-19 07:54:35May 18, 2021
Mad Hedge Fund Trader

An Up-and-Comer Biopharma Stock

Biotech Letter

AbbVie (ABBV) is the seventh biggest biopharmaceutical company worldwide in terms of revenue.

If you’re on the lookout for stocks that also offer juicy dividends, then this is a good company to add to your list alongside Dividend Aristocrats like Johnson & Johnson (JNJ) and Pfizer (PFE).

Since its split from Abbott Labs (ABT) back in 2013, AbbVie has increased its revenue by roughly 2.5 times.

In just a few years post-spin-off, its profits have grown from $18.8 billion to an impressive $46 billion in the last fiscal year.

A huge chunk of AbbVie’s growth is attributed to its blockbuster drug Humira, which is the number one selling drug in 2020 with a whopping $19.8 billion in net revenue.

That’s why it comes as no surprise that the drug’s impending loss of patent exclusivity in the US in 2023 is a major pain point for AbbVie investors.

However, it looks like AbbVie has positioned itself well into a future without Humira.

Although Humira does lead AbbVie’s immunology portfolio, the company’s other products in this lineup are also promising.

Up-and-coming drugs Skyrizi and Rinvoq both reported doubled annual sales from 2019 to 2020, with the two expected to bring in $15 billion by 2025.

Actually, Rinvoq is slated as the successor to Humira and is groomed as a “key growth driver” through 2026.

Putting money where its mouth is, AbbVie has performed notably in the first quarter of 2021 with a 50% increase from its 2020 net revenue to hit over $12.94 billion.

Its net profit also saw a double-digit bump of 18% to reach $3.55 billion. 

Despite off-patent woes, Humira still enjoyed a 3.5% uptick in sales to rake in $4.9 billion for the quarter.

Meanwhile, AbbVie’s aesthetic product line showed off an impressive 35% jump during the period, adding over $1.1 billion to revenue.

Reflecting the good news this quarter, AbbVie boosted its profitability guidance for 2021.

From an adjusted per-share net profit in the range of $12.32 to $12.52, the company now estimates it to be somewhere between $12.37 and $12.57.

Diversification has also been explored, with AbbVie veering from immunology and venturing into other segments like oncology, eye care, neuroscience, and even aesthetics.

One way AbbVie has been filling the Humira revenue gap is via acquisitions.

In 2015, the company acquired Pharmacyclics. This deal added a blockbuster drug, Imbruvica, in AbbVie’s lineup.

In 2020, Imbruvica generated roughly $4.7 billion in sales.

With an estimated compound annual growth rate of 26.5%, Imbruvica is projected to reach approximately $31.8 billion in sales through 2025.

On top of that, AbbVie has filed a slew of patents to restrict generic competition against Imbruvica until at least 2035.

Another major acquisition is Allergan, which added roughly 120 new products under AbbVie’s banner following the deal’s completion in May 2020.

Collectively, these products brought in $16 billion in sales in 2019 for Allergan—a noteworthy performance that translated to AbbVie’s 2020 revenue, which grew from $33 billion in 2019 to $45.8 billion a year later.

Perhaps the most notable addition from the Allergan acquisition is Botox.

In 2019, this drug raked in roughly $2.7 billion in sales. Similar to Imbruvica’s potential, Botox also presents a powerful growth runway.

In fact, this Allergan blockbuster is estimated to generate more than $13.4 billion in revenue by 2026.

Apart from the additional 120 products it injected into AbbVie’s portfolio, Allergan also queued 60 more development programs, which could generate at least $2 billion in sales by 2023.

AbbVie is one of the more innovative and newer biopharmaceutical companies to take the biotechnology and healthcare market by storm. Given the company’s strong pipeline programs, it’s definitely poised for more robust growth.

Spun off from Abbott Labs in 2013, this company currently sits at a massive market capitalization of roughly $205 billion.

If its portfolio, pipeline programs, acquisitions, and recent first-quarter earnings reports can tell us anything, it’s that AbbVie still has a lot of room to grow. Hence, it’s good to buy the dip.

 

AbbVie company

 

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2021-05-18 15:00:332021-05-25 02:26:02An Up-and-Comer Biopharma Stock
Douglas Davenport

May 18, 2021

Diary, Newsletter, Summary
    • Global Market Comments
      May 18, 2021
      Fiat Lux

      Featured Trade:
      (ON THE AIR WITH CASEY STUBBS),
      (HOW TO HANDLE THE FRIDAY, MAY 21 OPTIONS EXPIRATION),
      (UNP), (TLT)


https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 Douglas Davenport https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Douglas Davenport2021-05-18 08:06:332021-05-18 02:53:29May 18, 2021
Douglas Davenport

On the Air with Casey Stubbs

Diary, Newsletter

I managed to catch up with my buddy, Casey Stubbs, the other day. Casey assembles trading talent from all over the country with his “How to Trade It” podcasts, and my turn was up.

Am I the most interesting person Casey ever met?

Over 30 minutes, we discussed some of my favorite trading tips, investment strategies, and tricks of the trade. I touched upon how I got started in the markets a half-century ago and some of my early trading adventures. He couldn’t resist delving into my long, varied, and iconoclastic past, and I mentioned some of my greatest trades of all time.

Please enjoy. To access the podcast, please visit this link.

 

Podcaster Casey Stubbs

 

https://www.madhedgefundtrader.com/wp-content/uploads/2021/05/casey-stubbs.jpg 519 515 Douglas Davenport https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Douglas Davenport2021-05-18 08:04:022021-05-18 02:52:58On the Air with Casey Stubbs
Page 5 of 12«‹34567›»

tastytrade, Inc. (“tastytrade”) has entered into a Marketing Agreement with Mad Hedge Fund Trader (“Marketing Agent”) whereby tastytrade pays compensation to Marketing Agent to recommend tastytrade’s brokerage services. The existence of this Marketing Agreement should not be deemed as an endorsement or recommendation of Marketing Agent by tastytrade and/or any of its affiliated companies. Neither tastytrade nor any of its affiliated companies is responsible for the privacy practices of Marketing Agent or this website. tastytrade does not warrant the accuracy or content of the products or services offered by Marketing Agent or this website. Marketing Agent is independent and is not an affiliate of tastytrade. 

Legal Disclaimer

There is a very high degree of risk involved in trading. Past results are not indicative of future returns. MadHedgeFundTrader.com and all individuals affiliated with this site assume no responsibilities for your trading and investment results. The indicators, strategies, columns, articles and all other features are for educational purposes only and should not be construed as investment advice. Information for futures trading observations are obtained from sources believed to be reliable, but we do not warrant its completeness or accuracy, or warrant any results from the use of the information. Your use of the trading observations is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness of the information. You must assess the risk of any trade with your broker and make your own independent decisions regarding any securities mentioned herein. Affiliates of MadHedgeFundTrader.com may have a position or effect transactions in the securities described herein (or options thereon) and/or otherwise employ trading strategies that may be consistent or inconsistent with the provided strategies.

Copyright © 2025. Mad Hedge Fund Trader. All Rights Reserved. support@madhedgefundtrader.com
  • Privacy Policy
  • Disclaimer
  • FAQ
Scroll to top